Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody
Check out our poster on a discovery journey in identifying a dual-antagonistic mAb for an IO check point receptor utilizing Curia proprietary platform technology including PentaMice® for maximum antibody diversity, TunaCHO™ for high yield transient expression, in silico humanization, epitope binning, and hybridoma antibody discovery services. Curia Biologics offers these capabilities as a one-stop shop for your next biologics discovery.
(Click on poster image for access to full document)
Visit this page for a deeper understanding of our Antibody Discovery & Engineering Services.
Supplemental Information:
Whitepaper: Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery
Fact Sheet: PentaMice – Own your molecules:Therapeutic antibody discovery
Brochure: TunaCHO℠ Platform for Transient Protein & Antibody Production
Brochure: Introduction to hybridoma technologies for antibody discovery